Keywords: Peregrine Phama, Bavituximab, Ph II, Trial discrepancies, Lung cancer, NSCLC
Peregrine Pharma plummets after revealing "discrepancies" in one bavituximab trial
Article | 25 September 2012
Shares of US drugmaker Peregrine Pharmaceuticals (Nasdaq: PPHM) went into free-fall in pre-market trading yesterday, dropping 85.7% to $0.82, when the company ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
